You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Details for Patent: 7,776,881


✉ Email this page to a colleague

« Back to Dashboard


Title:Hyperlipemia therapeutic agent
Abstract: A hypertriglyceridemia therapeutic agent made up of a synergistically effective blood-triglyceride decreasing amount of a combination of a pitavastatin and eicosapentaenoic acid (EPA), or an ester thereof.
Inventor(s): Aoki; Taro (Tokorozawa, JP), Yamaguchi; Junji (Higashimurayama, JP), Sasaki; Yusuke (Higashimurayama, JP)
Assignee: Kowa Co., Ltd. (Nagoya-shi, JP) Nissan Chemical Industries, Ltd. (Tokyo, JP)
Filing Date:Dec 05, 2005
Application Number:11/293,217
Claims:1. A hypertriglyceridemia therapeutic agent comprising a synergistically effective blood-triglyceride decreasing amount of a combination of a pitavastatin and eicosapentaenoic acid (EPA) or an ester thereof.

2. The therapeutic agent according to claim 1, wherein the pitavastatin is pitavastatin calcium and the eciosapentaenoic acid (EPA) or ester thereof is ethyl eicosapentaenoate.

3. The therapeutic agent of claim 1, wherein the eicosapentaenoic acid or an ester thereof is selected from the group consisting of the calcium salt of EPA, the sodium salt of EPA, the n-butyl ester of EPA, the isobutyl ester of EPA, the t-butyl ester of EPA, the glycerin ester of EPA, the ethyl ester of EPA, and combinations thereof.

4. The therapeutic agent of claim 1, wherein the eicosapentaenoic acid or an ester thereof is selected from the group consisting of the calcium salt of EPA, the sodium salt of EPA, the n-butyl ester of EPA, the isobutyl ester of EPA, the t-butyl ester of EPA, the glycerin ester of EPA, and combinations thereof.

5. The therapeutic agent of claim 1, wherein the ratio of pitavastatin to EPA or an ester thereof is 1:100.

6. The therapeutic composition of claim 5, comprising 1 to 20 mg of pitavastatin.

7. The therapeutic composition of claim 1, wherein the ratio of pitavastatin to EPA or an ester thereof is 1:100 to 1:2000.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.